RecruitingNot ApplicableNCT05483283

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care


Sponsor

University of Illinois at Chicago

Enrollment

600 participants

Start Date

Jan 18, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks


Eligibility

Sex: FEMALEMin Age: 30 Years

Inclusion Criteria19

  • Aim 1
  • female biological sex
  • identification as Latina
  • one genetic risk factor (i.e., personal history of breast cancer or family history of breast or ovarian cancer)
  • one SDH risk factor, based on the American Cancer Society's definitions (e.g., perceived financial struggles; transportation difficulties; exposure to violence; housing challenges; social isolation/challenges)
  • + years old, based on American Cancer Society (ACS) screening guidelines for high risk populations
  • No receipt of cancer genetic counseling AND no receipt of genetic testing
  • Aim 2
  • female biological sex
  • referral from Latina Aim 1 participants
  • eligibility to obtain BC screenings, based on ACS guidelines (e.g., optional annual
  • screenings at 40-44 years old, recommended annual screenings at 45-54 years old, every other year screening at 55 and older)
  • self-report not attending Session #3 (as this will not be recorded by the staff)
  • Aim 3
  • participant from Aim 1 or
  • participant from Aim 2
  • Aim 3
  • Not a participant from Aim 1 or
  • Not a participant from Aim 2

Interventions

OTHEREmpowerment and Navigation

Empowerment and Navigation

OTHERSOC

SOC


Locations(1)

University of Illinois

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05483283


Related Trials